Emergent BioSolutions Inc. EBS
Emergent BioSolutions Inc. (NYSE: EBS) is an infectious disease drug developer. Its lead program, Marketed MCM and naloxone portfolio (BioThrax, CYFENDUS, ACAM2000, ANTHRASIL, raxibacumab, CNJ-016, NARCAN, KLOXXADO), is marketed for Anthrax, smallpox/mpox, opioid overdose, other public health threats.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BioThrax (Anthrax Vaccine Adsorbed) | Anthrax prophylaxis | vaccine | Approved |
| CYFENDUS (AVA, adjuvanted) | Anthrax post-exposure prophylaxis | vaccine | Approved |
| ACAM2000 | Smallpox and mpox vaccination | vaccine | Approved |
| ANTHRASIL | Inhalational anthrax | biologic-other | Approved |
| Raxibacumab | Inhalational anthrax treatment and prophylaxis | antibody | Approved |
| CNJ-016 (VIGIV) | Complications of smallpox vaccination | biologic-other | Approved |
| NARCAN Nasal Spray 4 mg (OTC) | Opioid overdose | small molecule | Approved |
| KLOXXADO Nasal Spray 8 mg (Rx) | Opioid overdose | small molecule | Approved |
Recent results and decisions
- Oct 16, 2026n/a Richard Lindahl will step down as Chief Financial Officer effective December 31, 2026, and Frank Vargo will serve as Interim Chief Financial Officer beginning January 1, 2027.
Richard Lindahl, the Company's Chief Financial Officer, will step down from his role as the Company's principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved infectious disease companies
- Innoviva, Inc. INVA
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.